Diaceutics and PCC launch NGS Concordance Study to advance precision oncology and support informed biomarker testing

This collaborative industry initiative will assess concordance in variant detection across next-generation sequencing (NGS) panels and platforms used in routine clinical practice

Welcome to the Precision Cancer Consortium

Fostering global collaboration to ensure that precision oncology and biomarker-informed, data-driven, equitable patient identification are integrated into routine care and clinical research.